Nonaka H, Kuriyama K, Yanagisako T, Satoh T, Miyazaki Y, Nagai K, Tokunaga S, Murata K, Maeda T, Atogami S
Department of Hematology, Nagasaki University, School of Medicine.
Rinsho Ketsueki. 1990 Jun;31(6):807-12.
We have treated 20 adult patients with acute lymphoblastic leukemia (ALL) and 2 patients with lymphoblastic lymphoma with a protocol modified from L-10M of the Memorial Sloan Kettering Cancer Center. Eighteen patients (81.8%) entered complete remission (CR). Eight of them eventually relapsed (only 1 patient had a meningeal relapse) and died. Median CR duration was 19 months (median overall follow-up of 35 months and 50% remission duration was not yet determined. Median overall survival was 19 months. Three patients died of sepsis during remission induction, but all of other deaths were due to resistant or relapsed leukemia. The four patients who completed 3.5 year's modified L-10M protocol were free from relapse for 6-11 months (mean 8.7). Although further follow-up is necessary, we suggest that modified L-10M protocol is effective for adult ALL and long-term survival may be available.
我们采用了纪念斯隆凯特琳癌症中心L-10M方案改良后的方案，治疗了20例成年急性淋巴细胞白血病（ALL）患者和2例淋巴细胞淋巴瘤患者。18例患者（81.8%）进入完全缓解（CR）状态。其中8例最终复发（仅1例有脑膜复发）并死亡。CR持续时间的中位数为19个月（总随访时间中位数为35个月，50%的缓解持续时间尚未确定）。总生存时间中位数为19个月。3例患者在缓解诱导期死于败血症，但其他所有死亡均归因于耐药或复发的白血病。完成3.5年改良L-10M方案的4例患者无复发6 - 11个月（平均8.7个月）。尽管有必要进行进一步随访，但我们认为改良L-10M方案对成年ALL有效，可能实现长期生存。
